The skin gateway
to the Immune System

About us

Missing flash plugin. Please download the latest Adobe Flash Player:
Get Adobe Flash Player

Presentation

DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or for allergy diagnosis.

DBV Technologies is a French publicly owned company focused on the development of innovative products for the diagnosis and treatment of food allergies.

DBV Technologies was founded in 2002 by leading French pediatricians, Professor Christophe Dupont (Head of the Neonatology Department in Paris at Saint Vincent Hospital), Doctor Pierre-Henri Benhamou, and engineer Bertrand Dupont (Arts et Métiers Institute), with funding from ANVAR. Leading investors in DBV Technologies include Sofinnova, Innobio, ALK-Abello, Lundbeckfond Ventures, Apax Partners, Shire Plc, ALTO Invest, Cap Devisif and Creagro.
DBV Technologies’ novel approach to food allergy diagnosis and treatment is focused on eliciting an immune response by targeting the antigen-presenting cells in the skin epidermis. The antigens (allergens) are delivered to the skin using DBV Technologies’ unique worldwide patented delivery system, VIASKIN®.

Using its proprietary patented delivery system VIASKIN®, DBV Technologies’ approach is to deliver biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. VIASKIN® is a non-invasive delivery system that utilizes electrostatic forces to present and deliver active compounds to the epidermis of the skin, without breaking the basement membrane (blood-skin barrier). As presented compounds, such as allergens, do not cross the blood-skin barrier, the risk of anaphylactic shock in allergic patients is dramatically reduced.

Allergy Treatment

DBV Technologies is focused on developing targeted allergy therapies using VIASKIN® technology specifically for patients with IgE-mediated food allergies, via its Epicutaneous ImmunoTherapy (EPIT) for Peanut and Milk allergy treatments.

Two products are under development:

  • VIASKIN® Peanut is the first peanut desensitization product ever developed for peanut allergies, a huge unmet medical need;
  • VIASKIN® Milk is specifically designed for patients with severe IgE-mediated milk allergies. It is the first medical desensitization product designed for cow’s milk protein allergy. This condition affects a growing amount of children, living with severe social and quality of life restrictions as a consequence. Medically, cow’s milk allergy is proven to play a pathogenic role in a large amount of disorders that are very burdening for children.
Allergy Diagnosis

Based on the VIASKIN® technology, DBV is developing products for the diagnosis of allergies. Diallertest® Milk is the first “ready to use” Patch-Test for the diagnosis of cow’s milk allergy in children. Diallertest® Milk is DBV Technologies’ first marketed product in the Diallertest® portfolio. It was introduced into the market in 2004 and is currently sold in France. Additional Diallertest® products are currently in development for the diagnosis of other food allergies, including wheat and soybean allergy.

Support and Awards

DBV Technologies has received the following awards:

  • December 2012 : OSEO public funds, for the development of Viaskin HDM - €5.1 million in milestones
  • January 2012 : Innovation aid grant from OSEO public funds– 640 000 euros
  • 2006: May -

    Prize for Innovation (122.7 KB)


  • 2005: June - EUREKA label awarded by the European Research Ministers
  • 2004: Etoile du Design awarded for the ergonomics and design of the Diallertest®
  • 2004: Oseo ANVAR support funding innovation: €600k
  • 2003: ALTRAN Foundation Prize (engineering assistance in the value of €1 million in 2004)
  • 2003: Club 92 Prize for research carried out by the DBV team
  • 2003: Oseo ANVAR support funding innovation: €440k

DBV Technologies has a strong intellectual property portfolio with patents covering both the technology platform (VIASKIN® technology) and the EPIT desensitization method.

Funding History
Partnering


For more information on upcoming partnering opportunities, please click here.

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
France
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH www.ovh.com

Design : l’enchanteur www.lenchanteur.com

Contact


Terms of Use


Forward-Looking Statements.

This website contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. DBV assumes no obligation to update any forward-looking statements appearing on this website in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.



Updates.

DBV may make improvements and/or changes to this website at any time. Although we attempt to periodically update information on this website, the information, materials and services provided on or through this website may occasionally be inaccurate, incomplete or out of date. DBV does not have a duty to update information contained in this website, and DBV will not be liable for any failure to update such information. We make no representation as to the completeness, accuracy or currency of any information on this website, and we undertake no obligation to update or revise the information contained on this website, whether as a result of new information, future events or circumstances or otherwise. It is your responsibility to verify any information contained in this website before relying upon it.



Links.

This website may contain links to websites operated by other parties. The linked sites are not under the control of DBV, and DBV is not responsible for the content available on any other Internet sites linked to this website. Such links do not imply DBV’s endorsement of material on any other site, and DBV disclaims all liability with regard to your access to such linked websites. DBV provides links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this website is at your own risk.